Interleukin 22 Protects Colorectal Cancer Cells from Chemotherapy by Activating the STAT3 Pathway and Inducing Autocrine Expression of Interleukin 8

Tingyu Wu,Zhongchuan Wang,Yun Liu,Zubing Mei,Guanghui Wang,Zhonglin Liang,Ang Cui,Xuguang Hu,Long Cui,Yili Yang,Chen-Ying Liu

DOI: https://doi.org/10.1016/j.clim.2014.07.005

IF: 10.19

2014-01-01

Clinical Immunology

Abstract:Resistance to chemotherapy is the major cause of colorectal cancer (CRC) treatment failure. The cytokine IL-22, which is produced by T cells and NK cells, is associated with tumorigenesis and tumor progression in cancers. However, the role of IL-22 in chemoresistance has not been investigated. We found that IL-22 levels in tumor tissues and peripheral blood were associated with chemoresistance and indicate poor prognosis for patients who received FOLFOX chemotherapy. In CRC cells, IL-22 was able to attenuate the cytotoxic and apoptosis-inducing effects of 5-FU and OXA by activating the STAT3 pathway and subsequently increasing the expression of anti-apoptotic genes. In addition, IL-22 conferred resistance to 5-FU and OXA by inducing IL-8 autocrine expression through STAT3 activation. Our findings identify IL-22 as a novel chemoresistance cytokine and may be a useful prognostic biomarker for CRC patients receiving FOLFOX chemotherapy.